{"id":63324,"date":"2026-04-16T18:05:39","date_gmt":"2026-04-16T10:05:39","guid":{"rendered":"https:\/\/flcube.com\/?p=63324"},"modified":"2026-04-16T18:05:40","modified_gmt":"2026-04-16T10:05:40","slug":"luye-pharma-initiates-phase-ii-trial-of-ly03017-for-alzheimers-associated-psychosis-in-china-following-us-clinical-clearance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63324","title":{"rendered":"Luye Pharma Initiates Phase II Trial of LY03017 for Alzheimer’s-Associated Psychosis in China Following US Clinical Clearance"},"content":{"rendered":"\n

Luye Pharma Group Limited<\/strong> (HKG: 2186<\/a>) has announced the initiation of a Phase II clinical study<\/strong> for LY03017<\/strong>, its investigational therapy for psychotic disorders in Alzheimer’s disease (AD)<\/strong>, with the enrollment of the first patient in China. The novel compound, developed using Luye’s proprietary New Molecular Entity\/New Therapeutic Entity (NME\/NTE) technology platform<\/strong>, has also received clinical trial authorization from US regulatory authorities, enabling potential global development.<\/p>\n\n\n\n

Clinical Development Framework<\/h2>\n\n\n\n
Component<\/th>Detail<\/th><\/tr><\/thead>
Study Phase<\/strong><\/td>Phase II<\/td><\/tr>
Study Design<\/strong><\/td>Randomized, double-blind, parallel-group, placebo-controlled<\/td><\/tr>
Primary Indication<\/strong><\/td>Hallucinations and delusions associated with psychotic disorders in Alzheimer’s disease<\/td><\/tr>
Patient Population<\/strong><\/td>Adults with Alzheimer’s disease experiencing psychotic symptoms<\/td><\/tr>
Primary Objectives<\/strong><\/td>Preliminary efficacy and safety assessment<\/td><\/tr>
Geographic Scope<\/strong><\/td>China (with US clinical nod secured)<\/td><\/tr>
Development Platform<\/strong><\/td>Luye Pharma NME\/NTE technology platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile \u2013 LY03017<\/h2>\n\n\n\n